Skip to main content

Dr Sidhartha Mullapudi

Search This Blog

Cardiology updates 2026: What is New in Atrial Fibrillation

September 23, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

Cardiology Update 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

Comments

Post a Comment

Join the academic discussion. Share your clinical insights, questions, or perspectives below.

Popular Posts

AHA 2026 Scientific Statement: Infective Endocarditis

AHA 2026 Scientific Statement: Infective Endocarditis Diagnosis, Antibiotic Therapy, and Management Take-home messages for bedside and exam use 1. Incidence of IE has risen since the 2015 AHA statement. Drivers: injection-drug-use IE, older patients with more comorbidity, and more prosthetic valves and cardiac devices. 2. One-year mortality remains about 40 percent. Care is no longer prolonged IV antibiotics plus delayed surgery alone. 3. Use a multidisciplinary Endocarditis Team (cardiology, infectious diseases, cardiac surgery, imaging, microbiology, pharmacy). Team care is linked to better outcomes. 4. Diagnose with the 2023 Duke / ISCVID criteria. They add molecular microbiology and multimodality imaging and improve sensitivity versus the 2000 modified Duke criteria. 5. Echo is still first-line imaging (TTE then TEE). Repeat within about 1 week if the first study is normal or inconclusive and suspicion remains high. 6. In TAVR-associated IE, TTE...

Fifth Universal Definition of Myocardial Infarction (2026): A Comprehensive Clinical Guide

Fifth Universal Definition of Myocardial Infarction (2026): A Comprehensive Clinical Guide 1. What Is New in the 5th UDMI 2026 Definition? Retirement of Numerical Subtypes: The traditional numerical classification (Types 1, 2, 3, 4a–c, and 5) has been retired. Myocardial infarction is now classified into three pathophysiological clinical entities: Primary MI, Secondary MI, and Procedure-Related MI. Elimination of "Type 3 MI": Sudden cardiac death before biomarkers can be drawn is no longer termed Type 3 MI. These cases are now classified under Primary, Secondary, or Procedure-related MI based on clinical circumstances or post-mortem findings, with an ICD-11 code for "Unspecified MI" (BA41.Z) when unevaluated. Objective Diagnostic Criteria for Secondary MI: Secondary MI now requires objective confirmation of underlying obstructive coronary artery disease (CAD) or new regional wall motion abnormalities (RWMA) / loss of myocardial viability to prevent overdiagno...

50 Practice-Changing Landmark Trials in Cardiology: Evidence-Based Viva Protocols & Clinical Pearls

THE "LANDMARK 50" VIVA PROTOCOL: ESSENTIAL CARDIOLOGY CLINICAL TRIALS THE VIVA EVIDENCE FRAMEWORK To excel in clinical vivas and theory examinations, avoid reciting raw percentage lists. Ground your answers in the PICO structure and articulate the Practice-Changing Lesson. Grouping landmark evidence by domain ensures rapid retrieval during case presentations and bedside grilling. A. CORONARY ARTERY DISEASE & ACS 1. ISIS-2 (1988): Aspirin & Streptokinase in AMI * The Lesson: Aspirin administered early in acute myocardial infarction significantly reduces vascular mortality, exhibiting massive additive synergy when combined with fibrinolysis. * Key Findings: Combined therapy produced a 42% relative reduction in 5-week mortality. * Viva Q&A: * Q: What is the primary antiplatelet mechanism? * A: Irreversible inhibition of cyclooxygenase-1 (COX-1), blocking thromboxane A2 production. * Q: Did aspirin increase the...

Powered by Blogger